Free Chat Friday (Every Friday) -- Our live chat room with stock and option alerts! Fridays, starting at 9:30 am, go to: https://goo.gl/O3l5KC use the password: freechatfriday

Sucampo Pharmaceuticals, Inc. Class A
(NASDAQ : SCMP)

( )
SCMP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading SCMP News...
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.22%123.470.6%$675.47m
PFEPfizer Inc.
0.12%33.900.8%$611.42m
BMYBristol-Myers Squibb Company
0.70%56.061.4%$491.92m
MRKMerck & Co., Inc.
-0.42%62.320.6%$481.90m
LLYEli Lilly and Company
0.90%82.061.0%$349.31m
ABBVAbbVie, Inc.
-0.20%65.942.1%$342.36m
NVSNovartis AG Sponsored ADR
-0.03%77.040.2%$164.55m
GSKGlaxoSmithKline plc Sponsored ADR
0.27%40.890.2%$124.33m
AZNAstraZeneca PLC Sponsored ADR
-1.98%30.251.3%$106.00m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.23%38.690.1%$99.69m
SNYSanofi Sponsored ADR
0.81%47.290.2%$67.63m
AKTXAkari Therapeutics Plc Sponsored ADR
-0.07%14.992.2%$30.59m
LCILannett Company, Inc.
0.39%26.0538.7%$19.52m
SCMPSucampo Pharmaceuticals, Inc. Class A
0.50%10.1514.4%$6.81m
EPIXESSA Pharma Inc
0.00%2.090.0%$0.01m

Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.